参考资料：

[1] FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation. Retrieved October 21, 2019, from https://www.businesswire.com/news/home/20191021005792/en

[2] FDA approves new breakthrough therapy for cystic fibrosis. Retrieved October 21, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-breakthrough-therapy-for-cystic-fibrosis-300942263.html

▽关注【药明康德】微信公众号